SCHEMBL16246765

SCHEMBL16246765

CCOC(=O)c1cc(C)c(C(O)c2ccc(CCl)cc2)n1CC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 1/20 0.42
NOD1 Q9Y239 1/20 0.42
MAPT P10636 7/20 0.41
KDM4E B2RXH2 6/20 0.41
TDP1 Q9NUW8 4/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 6/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 4/20 0.39
ALDH1A1 P00352 2/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.38
F10 P00742 1/20 0.38
HSD17B10 Q99714 2/20 0.36
RECQL P46063 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP4F2 P78329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16246842 0.79 KLK1 (0.47) NOD2NOD1MAPTKDM4ETDP1
SCHEMBL16246750 0.77 F10 (0.43) NOD2NOD1MAPTKDM4ETDP1
SCHEMBL11623145 0.67 MMP8 (0.49) TSHRSMN1; SMN2LMNAALDH1A1HTT
SCHEMBL4443427 0.67 CA1 (0.63) MAPTTDP1NPSR1SMN1; SMN2LMNA
SCHEMBL3254724 0.67 CA1 (0.63) MAPTTDP1NPSR1SMN1; SMN2LMNA
SCHEMBL7625059 0.66 FAAH (0.46) TSHRSMN1; SMN2LMNAHTT
SCHEMBL23013330 0.66 USP2 (0.42) NOD2NOD1MAPTKDM4ETDP1
SCHEMBL11368695 0.65 GAA (0.42) MAPTKDM4ETDP1MAPK1SMN1; SMN2
SCHEMBL16740485 0.63 HPGD (0.42) MAPTKDM4ETDP1NPSR1MAPK1
SCHEMBL8872998 0.63 CA12 (0.58) MAPTKDM4ETDP1NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3305778-B1 INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LTD (GB) 2022-01-19 EP disclosed
EP-3305778-A1 INHIBITORS OF PLASMA KALLIKREIN Kalvista Pharmaceuticals Limited (GB) 2018-04-11 EP disclosed
EP-2999697-B1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LTD (GB) 2017-04-19 EP disclosed
US-9533987-B2 Heterocyclic derivates KALVISTA PHARMACEUTICALS LIMITED (GB) 2017-01-03 US disclosed
US-20160108036-A1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LIMITED (GB) 2016-04-21 US disclosed
EP-2999697-A1 HETEROCYCLIC DERIVATES Kalvista Pharmaceuticals Limited (GB) 2016-03-30 EP disclosed
WO-2014188211-A1 HETEROCYCLIC DERIVATES KALVISTA PHARMACEUTICALS LIMITED (GB) 2014-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108036-A1 HETEROCYCLIC DERIVATES BDKRB1, KLKB1, BDKRB2 NOD2 3775/4885NOD1 2475/4885MAPT 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.